Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Compares two psoriasis drugs, deucravacitinib and ustekinumab, for long-term safety

Tests deucravacitinib against ustekinumab over time in adults with plaque psoriasis.

Plain-language title generated from the registry record
Registry title: Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Key facts

Where
Beijing, Bengbu, Changchun, Changsha Shi, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiaxing, Jinan, Nanjing, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Wenzhou, Wuhan, Xi'an, Zhengzhou, and Zhenjiang, ChinaSee the 33 sites
Phase
Phase 3

Where in China

  • Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaTaking people
  • Beijing Tongren Hospital WestBeijing, ChinaTaking people
  • Peking University Third HospitalBeijing, ChinaTaking people
  • The First Afflilated Hospital of Bengbu Medical CollegeBengbu, ChinaTaking people
  • ChangchunChangchun, ChinaNo longer taking part
  • Changsha ShiChangsha Shi, ChinaNo longer taking part
  • ChengduChengdu, ChinaNo longer taking part
  • The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaTaking people
  • The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaTaking people
  • Dermatology Hospital of Southern Medical UniversityGuangzhou, ChinaTaking people
  • Guangzhou First Peoples HospitalGuangzhou, ChinaTaking people
  • Hangzhou Third People's HospitalHangzhou, ChinaTaking people
  • People's Hospital of Zhejiang ProvinceHangzhou, ChinaTaking people
  • The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaTaking people
  • The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
  • HarbinHarbin, ChinaNot yet recruiting
  • The First Hospital Of JiaxingJiaxing, ChinaTaking people
  • Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
  • JinanJinan, ChinaNo longer taking part
  • NanjingNanjing, ChinaNo longer taking part
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
  • The First Hospital of China Medical UniversityShenyang, ChinaTaking people
  • Shenzhen Nanshan People's HospitalShenzhen, ChinaTaking people
  • The University of Hong Kong-Shenzhen HospitalShenzhen, ChinaTaking people
  • The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaTaking people
  • First Hospital of Shanxi Medical UniversityTaiyuan, ChinaTaking people
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and TechnologyWuhan, ChinaTaking people
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
  • Wuhan NO.1 HospitalWuhan, ChinaTaking people
  • The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaTaking people
  • ZhengzhouZhengzhou, ChinaNot yet recruiting
  • Affiliated Hospital of Jiangsu UniversityZhenjiang, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Bristol-Myers Squibb
Trial code
NCT07116967EU 2023-503766-24-00
Record updated
28 October 2026
Original description
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasisRead full original descriptionShow less

A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Inclusion: Participants with moderate-to-severe plaque psoriasis:; Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab; Have at least 1 of the following cardiovascular risk factors:; Current cigarette smoker; Diagnosis of hypertension; Diagnosis of hyperlipidemia; Diabetes mellitus type 1 or 2; History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack; Obesity; Family history of premature coronary heart disease or sudden death in a first-degree male relative younger than 55 years of age or in a first-degree female relative younger than 65 years of age.

Exclusion: Participants must not have recent history of 1 of the following cardiovascular events: MI, stroke, or coronary revascularization, or VTE within 90 days prior to Day 1; Participants must not have unstable CVD, defined as a recent clinical cardiovascular event (eg, unstable angina, rapid atrial fibrillation), or a cardiac hospitalization (eg, pacemaker implantation, HF) within 90 days prior to Day 1; Participants must not have evidence of active cancer or history of cancer (solid organ or hematologic malignancy including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence); Other protocol define inclusion/exclusion criteria apply.

ClinicalTrials.gov NCT07116967 · EU CTIS 2023-503766-24-00